NDAORALCAPSULE
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
27
Data completeness
7/8 — Comprehensive
LITFULO (ritlecitinib) by Pfizer is inhibitor. First approved in 2023.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LITFULO (ritlecitinib) is an oral small-molecule JAK3 and TEC kinase inhibitor approved by the FDA in June 2023 for alopecia areata. It works by irreversibly blocking ATP binding to JAK3 and TEC family kinases, suppressing cytokine-driven immune signaling implicated in hair loss.
$0.224MPart D
Growth15.3 years to LOEEarly-stage growth product with minimal Medicare uptake; commercial team is building market awareness and prescriber relationships in a newly validated indication.
Mechanism of Action
inhibitor. Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (27)
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Started Dec 2025
300 enrolled
Alopecia Areata
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Started Nov 2025
240 enrolled
Hidradenitis Suppurativa
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Started Oct 2025
200 enrolled
Chronic Spontaneous Urticaria
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Started Sep 2025
140 enrolled
Severe Alopecia Areata
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
Started Aug 2025
3,000 enrolled
Severe Alopecia Areata
Worked on LITFULO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.